David Jonathan Heineman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Jonathan Heineman has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Marlene Daniels
Department of Pulmonary Diseases, Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, the Netherlands
4 shared publications Wilhelmina Hendrika Schreurs
Department of Surgery, Noordwest Ziekenhuisgroep, Wilhelminalaan 12, 1815 JD, Alkmaar, the Netherlands
4 shared publications- Michael Wilhemus Jacobus Maria Wouters
Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands
3 shared publications - Rudolf W. Poolman
Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications Kees-Jan Ponsen
2 shared publicationsMartijn Geert Ten Berge
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
2 shared publications
Latest Publications
- 1 September 2019
- Published by Elsevier in Lung Cancer
- Vol. 135, 181-187
Impact of health care organization on surgical lung cancer care
- 1 September 2019
- Published by Elsevier in Lung Cancer
- Vol. 135, 181-187
Impact of health care organization on surgical lung cancer care
- 1 June 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (S16) , S2083-S2085
Invited letter to the editor on the editorial on “Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy”
Invited letter to the editor on the editorial on “ Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy ”
- 1 June 2018
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 10 (S16) , S2083-S2085
Invited letter to the editor on the editorial on “Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy”
Invited letter to the editor on the editorial on “ Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy ”
- Open Access
- 2 August 2017
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 9 (9) , 599-609
Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I–III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy. For stage I disease, staging is most accurate. Primary treatment consists of surgery or stereotactic ablative radiotherapy. When a patient has stage II disease, staging is less accurate because more diagnostic modalities are necessary to stage the mediastinal lymph nodes. Surgery remains the primary treatment modality and platinum-based adjuvant chemotherapy gives a 4% 5-year survival benefit. Staging patients with stage III disease is difficult because of the heterogeneity of the patients. It should be decided if a patient has potentially resectable disease with or without risk of incomplete resection. Induction therapy with chemo(radio)therapy followed by surgical resection or definitive chemoradiotherapy are the treatments of choice. The 5-year survival can reach 44% in selected patients. Decisions in staging and treating patients with NSCLC should be made by a multidisciplinary team with sufficient expertise in all aspects of staging and treatment.
- 2 August 2017
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 9 (9) , 599-609
Open AccessClinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I–III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy. For stage I disease, staging is most accurate. Primary treatment consists of surgery or stereotactic ablative radiotherapy. When a patient has stage II disease, staging is less accurate because more diagnostic modalities are necessary to stage the mediastinal lymph nodes. Surgery remains the primary treatment modality and platinum-based adjuvant chemotherapy gives a 4% 5-year survival benefit. Staging patients with stage III disease is difficult because of the heterogeneity of the patients. It should be decided if a patient has potentially resectable disease with or without risk of incomplete resection. Induction therapy with chemo(radio)therapy followed by surgical resection or definitive chemoradiotherapy are the treatments of choice. The 5-year survival can reach 44% in selected patients. Decisions in staging and treating patients with NSCLC should be made by a multidisciplinary team with sufficient expertise in all aspects of staging and treatment.
- 1 November 2016
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 102 (5) , 1615-1621
Clinical Staging of Stage I Non-Small Cell Lung Cancer in the Netherlands—Need for Improvement in an Era With Expanding Nonsurgical Treatment Options: Data From the Dutch Lung Surgery Audit
- 1 November 2016
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 102 (5) , 1615-1621
Clinical Staging of Stage I Non-Small Cell Lung Cancer in the Netherlands—Need for Improvement in an Era With Expanding Nonsurgical Treatment Options: Data From the Dutch Lung Surgery Audit
- 1 November 2016
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 102 (5) , 1622-1629
The Quality of Staging Non-Small Cell Lung Cancer in the Netherlands: Data From the Dutch Lung Surgery Audit
- 1 November 2016
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 102 (5) , 1622-1629
The Quality of Staging Non-Small Cell Lung Cancer in the Netherlands: Data From the Dutch Lung Surgery Audit
- Open Access
- 23 May 2012
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 83 (3) , 317-318
Plate fixation or intramedullary fixation of humeral shaft fractures – an update
- 23 May 2012
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 83 (3) , 317-318
Open AccessPlate fixation or intramedullary fixation of humeral shaft fractures – an update
- 1 December 2010
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 24 (12) , e119-e122
Intra-abdominal Migration of a Lag Screw in Gamma Nailing: Report of a Case
An 83-year-old female patient was referred to the emergency room with progressive pain on mobilization. Three weeks before presentation, she had been treated with a gamma nail for an unstable right intertrochanteric fracture. Pelvic x-ray showed an intra-abdominally migrated lag screw. No evidence of intra-abdominal lesions was visible on computed tomographic scan. The lag screw as well as the intramedullary nail was extracted and in a second operation, a total hip arthroplasty was implanted. Unfortunately, the total hip implant dislocated and needed reduction. The three consecutive operations seriously weakened the soft tissue envelope. A plaster cast and brace, immobilizing the right hip and pelvis, were provided to prevent recurrences of dislocation. After 6 weeks of immobilization, the patient did well. No late complication occurred. A review of the literature with an emphasis on pathophysiology of intra-abdominal or retroperitoneal migration of lag screws in gamma nailing is presented.
- 1 December 2010
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 24 (12) , e119-e122
Intra-abdominal Migration of a Lag Screw in Gamma Nailing: Report of a Case
An 83-year-old female patient was referred to the emergency room with progressive pain on mobilization. Three weeks before presentation, she had been treated with a gamma nail for an unstable right intertrochanteric fracture. Pelvic x-ray showed an intra-abdominally migrated lag screw. No evidence of intra-abdominal lesions was visible on computed tomographic scan. The lag screw as well as the intramedullary nail was extracted and in a second operation, a total hip arthroplasty was implanted. Unfortunately, the total hip implant dislocated and needed reduction. The three consecutive operations seriously weakened the soft tissue envelope. A plaster cast and brace, immobilizing the right hip and pelvis, were provided to prevent recurrences of dislocation. After 6 weeks of immobilization, the patient did well. No late complication occurred. A review of the literature with an emphasis on pathophysiology of intra-abdominal or retroperitoneal migration of lag screws in gamma nailing is presented.
- Open Access
- 30 June 2010
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 81 (4) , 517
Treatment of humeral shaft fractures–meta-analysis reupdated
- 30 June 2010
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 81 (4) , 517
Open AccessTreatment of humeral shaft fractures–meta-analysis reupdated
- Open Access
- 1 April 2010
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 81 (2) , 216-223
Plate fixation or intramedullary fixation of humeral shaft fractures
The optimal approach to operative treatment of humeral shaft fractures remains debatable. Previously published trials have been limited in size and have been inconclusive regarding important patient outcome variables following treatment with either intramedullary nails or plates. We conducted a meta-analysis of available trials comparing treatment of humeral shaft fractures. We performed a literature search from 1967 to November 2007 in the main medical search engines and selected 4 randomized trials that compared nails and plates in patients with humeral shaft fractures and that reported on complications due to surgery. We statistically pooled patient data using standard meta-analytic approaches. Our primary outcome was the total complication rate, comprised of all complications listed in the articles included. Secondary outcomes included non-union, infection, nerve palsy, and reoperation rate. Methodology was assessed using the CLEAR NPT. When pooling the data of the 4 trials (n = 203 patients), we did not find a statistically significant difference between implants in the rate of total complications, non-union, infection, nerve-palsy, or the need for reoperation. The studies included were small and had methodological limitations. Our meta-analysis suggests stastistically insignificant differences between plates and nails in the treatment of humeral shaft fractures. Small sample sizes, study heterogeneity, and methodological limitations argue strongly for a definitive, large trial. We recommend that this trial should be a randomized controlled trial with appropriate allocation of patients and blinding of patients and care providers and outcome assessors, and that it should include patient-important outcomes.
- 1 April 2010
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 81 (2) , 216-223
Open AccessPlate fixation or intramedullary fixation of humeral shaft fractures
The optimal approach to operative treatment of humeral shaft fractures remains debatable. Previously published trials have been limited in size and have been inconclusive regarding important patient outcome variables following treatment with either intramedullary nails or plates. We conducted a meta-analysis of available trials comparing treatment of humeral shaft fractures. We performed a literature search from 1967 to November 2007 in the main medical search engines and selected 4 randomized trials that compared nails and plates in patients with humeral shaft fractures and that reported on complications due to surgery. We statistically pooled patient data using standard meta-analytic approaches. Our primary outcome was the total complication rate, comprised of all complications listed in the articles included. Secondary outcomes included non-union, infection, nerve palsy, and reoperation rate. Methodology was assessed using the CLEAR NPT. When pooling the data of the 4 trials (n = 203 patients), we did not find a statistically significant difference between implants in the rate of total complications, non-union, infection, nerve-palsy, or the need for reoperation. The studies included were small and had methodological limitations. Our meta-analysis suggests stastistically insignificant differences between plates and nails in the treatment of humeral shaft fractures. Small sample sizes, study heterogeneity, and methodological limitations argue strongly for a definitive, large trial. We recommend that this trial should be a randomized controlled trial with appropriate allocation of patients and blinding of patients and care providers and outcome assessors, and that it should include patient-important outcomes.